Literature DB >> 12735861

Luteal support with vaginal micronized progesterone gel in assisted reproduction.

Alan S Penzias1, Michael M Alper.   

Abstract

The purpose of this study was to review the rationale for vaginal progesterone treatment as luteal support in IVF, and the clinical experience with vaginal micronized progesterone gel. It was found that luteal support with exogenous progesterone significantly improves implantation and pregnancy rates after IVF. Vaginal administration offers a number of potential advantages over intramuscular injection in terms of tolerability and convenience. The clinical experience with Crinone 8%, a vaginal gel containing 90 mg micronized progesterone in a polycarbophil base, indicates that the use of this preparation is associated with pregnancy rates comparable with those achieved after intramuscular administration of progesterone. Moreover, in studies in which patient preferences have been assessed, significantly higher preferences for vaginal micronized progesterone gel have been reported, compared with intramuscular administration or vaginal suppositories. In conclusion, the vaginal micronized progesterone gel used in this study provided effective and well-tolerated luteal support in women undergoing IVF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12735861     DOI: 10.1016/s1472-6483(10)61847-0

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  8 in total

1.  Pregnancy outcomes in oocyte donation recipients: vaginal gel versus intramuscular injection progesterone replacement.

Authors:  Brian M Berger; James A Phillips
Journal:  J Assist Reprod Genet       Date:  2012-02-04       Impact factor: 3.412

2.  Route of progesterone administration for luteal phase support may affect outcome of controlled ovarian hyperstimulation for IVF with ICSI using GnRH antagonist.

Authors:  Mustafa Bahceci; Ulun Ulug
Journal:  J Assist Reprod Genet       Date:  2008-10-22       Impact factor: 3.412

3.  Luteal phase bleeding after IVF cycles: comparison between progesterone vaginal gel and intramuscular progesterone and correlation with pregnancy outcomes.

Authors:  Sami Jabara; Kurt Barnhart; Joan C Schertz; Pasquale Patrizio
Journal:  J Exp Clin Assist Reprod       Date:  2009-10-20

4.  Comparison of intravaginal progesterone gel and intramuscular 17-α-hydroxyprogesterone caproate in luteal phase support.

Authors:  Funda Satir; Tayfun Toptas; Murat Inel; Munire Erman-Akar; Omur Taskin
Journal:  Exp Ther Med       Date:  2013-04-04       Impact factor: 2.447

5.  Patients' administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for Luteal phase support.

Authors:  Angeline N Beltsos; Mark D Sanchez; Kevin J Doody; Mark R Bush; Alice D Domar; Michael G Collins
Journal:  Reprod Health       Date:  2014-11-11       Impact factor: 3.223

6.  A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest®) for luteal phase support during IVF treatment.

Authors:  Polly Heine; Laura Sellar; Sue Whitten; Priti Bajaj
Journal:  Patient Relat Outcome Meas       Date:  2017-12-08

7.  Treatment outcomes of blastocysts thaw cycles, comparing the presence and absence of a corpus luteum: a systematic review and meta-analysis.

Authors:  Joscelyn Gan; Genia Rozen; Alex Polyakov
Journal:  BMJ Open       Date:  2022-04-26       Impact factor: 3.006

8.  Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety.

Authors:  Helen Y How; Baha M Sibai
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.